Roth Capital Keeps LIgand Pharma (LGND) at Buy; Glaxo Initiates Promacta Phase III
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Futures falter as Meta Platforms weighs on megacaps
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen at multi-decade lows, dollar drops before US data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Ligand Pharma (LGND) Affirms Start of Eltrombopag + Azacitidine Phase 3 in MDS
June 25, 2014 8:37 AM EDTLigand Pharma (Nasdaq: LGND) that its partner GlaxoSmithKline (NYSE: GSK) plc has started a Phase 3 study to evaluate the platelet supportive care effects of eltrombopag (Promacta/Revolade) in combination with azacitidine (the current standard of care) versus placebo in combination with azacitidine in intermediate-1, intermediate-2 or high-risk patients with myelodysplastic syndromes (MDS). The global SUPPORT (TRC112121) study will assess the proportion of patients who are platelet transfusion free during the first four cycles of treatment.
MDS is a type of cancer in which the bone... More
Roth 'Encouraged' by TG Therapeutics (TGTX), Ligand (LGND) Deal; Issues Commentary
June 24, 2014 9:34 AM EDTRoth Capital affirms TG Therapeutics (Nasdaq: TGTX) at Focus Pick with target price of $20 following news of a partnership with Ligand Pharma (Nasdaq: LGND).
Analyst Joseph Pantginis commented, We are impressed with the deal struck with Ligand and believe the IRAK4 candidate... More
